BRIEF published on 08/10/2026 at 08:35, 19 hours 4 minutes ago Innate Pharma Advances Lacutamab into Phase 3 Trial with Sobi Innate Pharma Lacutamab Phase 3 TELLOMAK-3 Markus Jensen Sobi Partnership
BRIEF published on 08/10/2026 at 08:35, 19 hours 4 minutes ago Innate Pharma Avance Lacutamab en Phase 3 avec Sobi Innate Pharma Lacutamab Phase 3 TELLOMAK-3 Markus Jensen Partenariat Sobi
PRESS RELEASE published on 08/10/2026 at 08:30, 19 hours 9 minutes ago Informations privilégiées / Autres communiqués Innate Pharma fait progresser Lacutamab vers la phase 3 suite au partenariat avec Sobi et nomme un nouveau directeur médical. Démarrage de l'étude TELLOMAK-3 pour le syndrome de Sézary Partenariat Phase 3 Innate Pharma Directeur Médical Lacutamab
BRIEF published on 05/19/2026 at 07:05, 2 months 22 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
BRIEF published on 05/19/2026 at 07:05, 2 months 22 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 2 months 22 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 2 months 22 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 2 months 22 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
PRESS RELEASE published on 05/19/2026 at 07:00, 2 months 22 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
BRIEF published on 04/17/2026 at 21:05, 3 months 23 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
Published on 08/11/2026 at 00:40, 2 hours 59 minutes ago CORRECTION FROM SOURCE: Fermi Announces Binding Lease Agreement with TensorWave
Published on 08/11/2026 at 00:25, 3 hours 14 minutes ago Empress Reports 2026 Second Quarter Financial Results
Published on 08/10/2026 at 23:35, 4 hours 4 minutes ago NioCorp Project to Expand Production to 8 Made-in-USA Critical Minerals Over a 40-Year Mine Life with an Estimated $4.1 Billion Pre-Tax NPV8%
Published on 08/10/2026 at 23:30, 4 hours 9 minutes ago Condor and Element79 Agree on Restructured Terms for Lucero Project
Published on 08/10/2026 at 23:25, 4 hours 14 minutes ago Ur-Energy Reports Second Quarter 2026 Results
Published on 08/10/2026 at 22:15, 5 hours 24 minutes ago Amrize Files Form 10-Q for Second Quarter 2026
Published on 08/10/2026 at 22:05, 5 hours 34 minutes ago Immunic Appoints Elena Ridloff to Board of Directors
Published on 08/10/2026 at 20:24, 7 hours 15 minutes ago EQS-Adhoc: PNE AG updates on ongoing sales process
Published on 08/10/2026 at 19:35, 8 hours 4 minutes ago Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 19:00, 8 hours 39 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:00, 9 hours 39 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 9 hours 39 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 9 hours 54 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 15 hours 45 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
